Phage Therapeutics Opportunity PHAXIAM Therapeutics is advancing bacteriophage-based treatments targeting highly resistant hospital infections, presenting a distinctive partnering and licensing avenue for pharmaceutical players seeking innovative antimicrobial platforms.

Strategic Disease Focus The portfolio targets Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which together drive a large share of resistant hospital-acquired infections, indicating clear collaboration angles with hospitals, biotechs, and contract research/production services aiming to augment antimicrobial pipelines.

Public Market Presence Listed on Nasdaq Capital Market and Euronext Paris, PHAXIAM's visibility and cross-border access can facilitate co-development, co-commercialization deals, and secondary partnerships with global biopharma players and regional distributors.

Collaborative Initiatives Recent Phagogram Day collaboration with Phage Canada demonstrates active engagement in standardizing phage susceptibility testing, offering opportunities to provide diagnostic collaborations, laboratory services, and joint ventures around phage development and clinical assay capabilities.

Funding & Growth Capacity With substantial funding and mid-market revenue, PHAXIAM has financial solidity to support partner-driven programs, translational studies, and early-stage commercialization activities, making it a viable target for licensing deals, milestone-based collaborations, and research partnerships.